Prevention of cardiovascular disease often ultimately comes down to managing LDL cholesterol. The problem is not that we lack medication, but that people find it difficult to continue treatment steadily for a lifetime. Gene editing is asking whether this old weakness can be overcome with “a single intervention.”

Imagine a house with a leak. If you diligently wipe away the water pooling on the floor, you can hold out for a while. But the real solution does not lie in endlessly scooping out the water. It lies in finding where it is leaking and fixing that point. The recent imagination surrounding cholesterol treatment resembles this in some ways.

Until now, treatment has largely been a matter of steady management. You take medication, check your numbers, and adjust the dose if necessary. In fact, such treatments are effective. The fact that lowering LDL cholesterol reduces the risk of cardiovascular events such as heart attacks and strokes has already been confirmed through years of accumulated research and clinical experience. The problem is not a lack of treatment tools. It is that continuing that treatment steadily over many years is difficult.

People are more vulnerable to repetition than they seem. Whether it is blood pressure medicine, diabetes medicine, or cholesterol medicine, taking it every day may look simple, but maintaining that for a lifetime is not easy. In the rush of daily life, doses get missed. If there is no immediate change in the body, the sense of urgency weakens. Concerns about cost or side effects can also disrupt treatment. Preventive treatment often fails not because of a lack of drug efficacy, but because of a failure of persistence.

It is precisely here that gene editing poses a completely different question. Instead of managing numbers every day with medication, could we intervene once in the biological pathway that raises cholesterol and make it remain low for a long time? In other words, it is closer to trying to change the leaking structure itself rather than continuing to bail out the water. The core of this technology is not about creating a stronger drug. It is about trying to change the time structure of treatment from “lifelong medication” to “a single intervention.”

This approach is no longer a vague story about the future. In November 2025, the international journal Nature closely examined the growing effort to use gene editing to lower high LDL cholesterol, one of the common causes of heart disease. The case highlighted in the article was VERVE-102, a candidate developed by the U.S. biotech company Verve Therapeutics. This treatment is an in vivo gene-editing approach that aims to lower cholesterol over the long term by editing the PCSK9 gene, which is involved in LDL regulation in the liver.

Who did it? Verve Therapeutics led the development, and as early clinical data were released, it emerged as one of the leading examples in this field. What is it trying to do? It aims to target the PCSK9 pathway inside liver cells so that LDL can be kept low for a long time. To whom was it applied? It was examined mainly in patients with heterozygous familial hypercholesterolemia and in people at high risk of early coronary artery disease. When and where did it draw attention? Based on interim results from early clinical trials released in 2025, Nature gave this trend full attention in November of the same year. Why is it important? Because the limit of existing treatment may lie less in a lack of efficacy than in the difficulty of sustaining it. What kind of results came out? In the published interim results, LDL levels decreased in a dose-dependent manner after a single administration, and in some patients in the highest-dose group, a reduction of up to 69 percent was reported.

If you follow this six-part framework, gene editing begins to appear not as a vague future technology but as a highly concrete treatment strategy. The goal is not simply to make lab numbers look better. It is to ask whether a physiological state that can reduce the long-term risk of cardiovascular events can be designed through a single intervention. If treatment until now has been a structure that requires continuous management, this technology is testing whether a structure can be created in which a low state is maintained from the outset for a long time.

This is the key point. When many people think about cholesterol treatment, they still assume that what is needed is simply “a better drug.” Of course, safer and more convenient drugs would help. But this field already has fairly powerful medications. Statins have long been the standard treatment, and other classes of drugs have steadily been added. The problem is that there is a much wider gap than people think between the fact that such drugs exist in theory and the fact that they work properly over long periods in real life.

Preventive treatment is, by nature, an inconvenient structure. It does not immediately reduce pain, nor does it make visible symptoms disappear before your eyes. Most of the time, the reason you take medicine today is not to feel different tomorrow, but to reduce a risk several years down the line. That is why treatment is often pushed down the list of priorities in life. On busy days, it gets forgotten. When the numbers improve, people relax. If the body does not seem particularly unwell, vigilance fades. For prevention to succeed, everyday repetition must endure just as much as medical efficacy must. And it is precisely in that repetition that human beings so often waver.

That is why the question gene editing asks is, surprisingly, a very realistic one. If we take as a given that people waver, then would a treatment maintained for a long time through a single intervention not be more practical than one that must be repeated every day? In other words, this technology is targeting not only cholesterol levels themselves. It is also targeting the human condition that makes long-term treatment hard to sustain. The future of cholesterol management is likely to shift from a competition to find stronger drugs to a competition to create states that can be maintained longer.

But the fact that a single treatment lasts a long time also means that a single decision remains with the body for a long time. That is both the greatest appeal of gene editing and its greatest burden. If a drug taken today does not suit you, you can stop it tomorrow. Gene editing, however, cannot be reversed so easily. In preventive treatment, this difference is especially decisive.

In diseases like cancer, which immediately threaten life, treatments with strong side effects are relatively easier to accept. Cholesterol management, by contrast, is generally not about “saving a life right now,” but about “reducing future risk.” Accordingly, the standard for acceptable risk inevitably becomes much stricter. It is not enough that numbers fall well in an early trial. We must ultimately confirm whether it remains safe after a long period, whether unexpected problems appear later, and how the editing effect is maintained over time.

Nor does the same risk-benefit calculation apply to everyone. For someone with a very strong family history, high LDL levels from a young age, and a high risk of early cardiovascular events, one strong intervention may be entirely reasonable. For an average-risk group, however, it may look like an option that is still too far ahead of its time. The same technology may be an urgent option for some and still an early choice for others.

In the end, for this technology to take its place in medical practice, efficacy alone is not enough. Social agreement is also needed on who should become the first target population. Medicine is not adopted widely the moment something becomes possible. Only when it is clarified which patient groups, at what level of risk, and under what conditions should be allowed to receive it first, can it truly earn its place as a treatment option.

When people think of the future of this technology, many picture only laboratories and hospitals. But the real contest is likely to be decided outside them. Gene-editing treatment is not completed by papers and clinical trials alone. Manufacturing processes, quality control, supply chains, storage and transport, and regulatory standards all have to fit together. That is why this field is described as both medicine and manufacturing.

Conventional cholesterol drugs have operated within an industry capable of mass production and standardization. A system is already in place to supply a single pill stably to vast numbers of people. Gene-editing treatment, by contrast, is much more complex. Delivery vehicle design, raw material procurement, batch-to-batch consistency, and storage and transport conditions must all be managed at a high level. No matter how excellent the technology is, if manufacturing scale does not keep up, it will be difficult to expand it to a broad patient population.

This issue matters even more in the field of cholesterol treatment. Cholesterol management is not a niche concern affecting only a few people; it is connected to an enormous number of patients. An ultra-expensive treatment for a small number of patients may still carry medical significance. But it is unlikely to transform the preventive paradigm of society as a whole. For this technology to produce real change, it must go beyond a few symbolic successes and establish a cost structure and manufacturing system that a broader patient population can realistically access.

That is why the competition in this field does not end in the laboratory. It matters not only who can find a more precise target, but also who can make and supply the treatment more reliably. If manufacturing capability falls short, innovation quickly becomes privilege. No matter how dazzling the technology is, if only a few can use it, it cannot become a tool that changes the future of prevention.

The larger question posed by gene-editing cholesterol treatment lies outside medicine. How far can society permit irreversible interventions in people who are not yet sick? This question cannot be answered by technical sophistication alone.

People tend to be relatively accepting of aggressive treatment for severely ill patients. But when it comes to strong intervention for someone who appears outwardly healthy in order to reduce future risk, they become much more cautious. Prevention is inherently difficult to sell. The statement “you seem fine now, but your risk is high in the future” may be statistically correct, yet it does not easily resonate emotionally. Moreover, a technology like gene editing, whose effects remain after a single intervention, magnifies both expectation and fear.

To some, this may look like an innovation that can prevent heart disease before it begins. To others, it may still seem too early, too irreversible, and too forceful a technology for society to accept. In reality, preventive medicine has always moved more slowly in terms of social acceptance than science itself. Vaccines, health screenings, and early detection were all, at first, subjects of controversy. Gene editing is likely to be no exception.

And yet the social costs left by cardiovascular disease are enormous. A single heart attack can shake an individual’s life, increase the burden on a family, and lead to higher medical costs and productivity losses across society. As the benefits of prevention in high-risk groups become clearer, society may become more willing than before to consider active intervention. Prevention may outwardly appear to be a cautious language, but when the harm is large enough, it can instead become the logic that justifies more radical choices.

Realistically speaking, it is unlikely that gene editing will soon push out all cholesterol drugs. Statins and existing medications will remain the basic option for a wide range of people. They have long usage histories, relatively stable cost structures, and far greater accessibility. Medicine rarely overturns an existing system all at once.

A more realistic future looks different. Existing drug treatment remains the basic axis, while gene editing takes root as a powerful long-term option for specific high-risk groups. In other words, rather than being a revolution that overturns all treatment overnight, it is closer to adding a new layer to the treatment map. Yet this change at the outer edge is not small. Many medical innovations have always begun at the most difficult and most urgent frontier, and over time they have moved steadily inward.

Seen this way, the true significance of gene editing does not lie in eliminating drugs. More importantly, it lies in changing the timing of treatment. Current cholesterol management fundamentally stands on the premise of “lifelong management.” Gene editing, by contrast, asks a completely different question: can a long-lasting state be designed through a single intervention? This is not simply a technological upgrade. It is an attempt to change the very language of prevention.

Of course, this is still an early and cautious stage. Longer follow-up is needed, more data are needed, and the eligible population is likely to remain limited for some time. But major changes in medicine always begin like this. At first, they appear to be unfamiliar options for only a small group of high-risk patients, but the door they open eventually changes the standards of the mainstream. The significance of gene editing in the context of cholesterol is no different. The important question is not whether a single treatment can replace every drug. The more important question is how deeply and fundamentally this technology can rewrite the timetable of preventive treatment.

Nature, 2025-11-13, “CRISPR vs cholesterol: can gene editing prevent heart disease?”, Heidi Ledford